Shopping Cart 0
Cart Subtotal
USD 0

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2017

Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2017, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Overview 6

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Companies Involved in Therapeutics Development 20

AFFiRiS AG 20

ChemoCentryx Inc 20

Dompe Farmaceutici SpA 21

Novo Nordisk A/S 21

Prommune Inc 22

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Drug Profiles 23

ALS-205-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

avacopan-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DF-2593A-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Drug to Antagonize C5aR for Periodontitis-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-67-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody to Antagonize C5aR for Rheumatoid Arthritis and Lewis Lung Cancer-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Vaccine to Target C5a for Alzheimer's Disease-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Dormant Products 36

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Discontinued Products 37

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Product Development Milestones 38

Featured News & Press Releases 38

Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan 38

May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 38

Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 39

Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan 39

Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan') 41

Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 42

Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 42

Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 44

Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 44

Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 46

May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 47

Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 49

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 49

Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 50

Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administrations, H2 2017 17

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by AFFiRiS AG, H2 2017 20

Pipeline by ChemoCentryx Inc, H2 2017 20

Pipeline by Dompe Farmaceutici SpA, H2 2017 21

Pipeline by Novo Nordisk A/S, H2 2017 21

Pipeline by Prommune Inc, H2 2017 22

Dormant Projects, H2 2017 36

Discontinued Products, H2 2017 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutic Products under Development, Key Players in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Overview, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Assessment


Companies

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutic Products under Development, Key Players in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Overview, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Assessment

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2017

Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Pipeline Review, H2 2017, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Overview 6

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Companies Involved in Therapeutics Development 20

AFFiRiS AG 20

ChemoCentryx Inc 20

Dompe Farmaceutici SpA 21

Novo Nordisk A/S 21

Prommune Inc 22

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Drug Profiles 23

ALS-205-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

avacopan-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DF-2593A-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Drug to Antagonize C5aR for Periodontitis-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-67-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody to Antagonize C5aR for Rheumatoid Arthritis and Lewis Lung Cancer-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Vaccine to Target C5a for Alzheimer's Disease-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Dormant Products 36

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Discontinued Products 37

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)-Product Development Milestones 38

Featured News & Press Releases 38

Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan 38

May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 38

Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 39

Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan 39

Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan') 41

Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 42

Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 42

Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 44

Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 44

Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 46

May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 47

Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 49

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 49

Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 50

Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administrations, H2 2017 17

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by AFFiRiS AG, H2 2017 20

Pipeline by ChemoCentryx Inc, H2 2017 20

Pipeline by Dompe Farmaceutici SpA, H2 2017 21

Pipeline by Novo Nordisk A/S, H2 2017 21

Pipeline by Prommune Inc, H2 2017 22

Dormant Projects, H2 2017 36

Discontinued Products, H2 2017 37

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutic Products under Development, Key Players in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Overview, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Assessment


Companies

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutic Products under Development, Key Players in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Overview, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline, C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Assessment

chat_bubbleLet's Chat